Preliminary data showed that as low as 1 ×107 CD19-CAR-iNKTs/m2 induced complete remission in patients with refractory B cell malignancies, which included one acute lymphoblastic leukemia and three non-Hodgkin lymphoma (NHL) patients respectively (52). Here, CD19 is linked to non-Hodgkin lymphoma.